Pfizer Inc. Stock

Investors looking to pad their passive income streams with high-yield dividend stocks have three excellent choices. If you have an extra $100 to invest, you could set yourself up with dividends from

The healthcare industry is full of opportunities for long-term investors to become part-owner in compelling businesses that are changing the future for patients across countless disease areas. You

Your long-term investment portfolio should have meaningful exposure to healthcare stocks. People will always seek treatments for disease, so demand for the sector won't go away any time soon

Pfizer (NYSE: PFE) stock has struggled over the past year, losing around 28% of its value. Its dividend payout, meanwhile, has continued to rise again and again. This combination has pushed the

It's easy to find stocks that are lagging broader equities, even in a bull market like the one we're currently in. It's harder to find beaten-down stocks that still look worth buying and holding

Dividends may be boring but are essential to building a well-balanced portfolio. After all, dividend payments have accounted for approximately 85% of the S&P 500's total returns since 1960, per a

After steadily raising its payout by 163% over the past 15 years, Pfizer (NYSE: PFE) continues to be one of the most reliable pharma stocks an income-seeking investor can reach for these days. The

Healthcare doesn't get the hype that other industries -- say, technology -- get. However, there arguably isn't an industry more important to humankind's well-being. That's especially true in the

Don't believe the adage to "sell in May and go away." Buying stocks can still be a smart move, especially if you're a long-term investor.

Three Motley Fool contributors have identified stocks they

Weight loss translates to investor profits. Just look at Eli Lilly and Novo Nordisk. Both stocks have skyrocketed thanks largely to their obesity drugs, with Lilly's share price more than

Pfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its stock in serious bargain territory. Speaking

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q1 2024 Earnings CallMay 01, 2024, 10:00 a.m. ET

Operator

Continue reading

Source Fool.com

Pfizer (NYSE: PFE) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied pharmaceutical company notch double beats on

Earnings season is officially here. As per usual, there have already been epic sell-offs and run-ups across well-known names.

However, long-term investors know that the best way to view a quarterly

I owned shares of Pfizer (NYSE: PFE) when the COVID-19 pandemic started. Watching the stock soar over 60% in roughly two years was fun. Seeing Pfizer's share price fall nearly 60% from its peak

Income investors can be growth investors, too. Granted, it's not always easy to find stocks that pay generous dividends and offer solid prospects of share price appreciation. However, such stocks

"If you don't find a way to make money while you sleep, you will work until you die." That's a quote from billionaire investor Warren Buffett which emphasizes the importance of making your money

If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840.

That answer will be terrible

Pfizer (NYSE: PFE) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to

Income-seeking investors have to make an important choice when shopping for stocks to buy. Shares of companies that are likely to raise their dividend payouts at a rapid pace tend to offer low

Pfizer (NYSE: PFE) stock is relatively cheap. I can easily back up that claim. The big drugmaker's shares trade at lower forward earnings multiples than the S&P 500 and the S&P 500 healthcare

Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have

Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in

One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.

If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made